FUS is an inclusion criterion in 3 clinical trials for myxoid liposarcoma, of which 3 are open and 0 are closed. Of the trials that contain FUS status and myxoid liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

FUS is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FUS status and Ewing sarcoma as inclusion criteria, 2 are phase 1 (2 open) [4].

FUS is an inclusion criterion in 1 clinical trial for Ewing sarcoma/peripheral primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains FUS status and Ewing sarcoma/peripheral primitive neuroectodermal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

FUS is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains FUS status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FUS is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains FUS status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

FUS is an inclusion criterion in 1 clinical trial for round cell liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains FUS status and round cell liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FUS is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FUS status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].